Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued Dosing of Gevokizumab in Uveitis (EYEGUARD-E)
NCT02258854Phase 3Terminated
- Sponsor
- XOMA
- Start
- Mar 2014
- Primary completion
- Oct 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gevokizumab in non-infectious intermediate uveitis, Posterior uveitis (non-infectious), non-infectious panuveitis (NIU) and 1 more, sponsored by XOMA. Primary endpoint: Treatment-emergent Adverse Events at 108 weeks. Started Mar 2014; status: terminated.
02
Drugs
gevokizumab
03
Conditions
non-infectious intermediate uveitisPosterior uveitis (non-infectious)non-infectious panuveitis (NIU)Behcet's disease (BD)
Beyond the preview
Go deeper on NCT02258854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02258854.